A Phase I/II trial of Cetuximab, Carboplatin and Radiotherapy for patients with locally advanced Head and Neck Squamous Cell Carcinoma.

The purpose of this study is to assess the safety and feasibility of combining radiotherapy and carboplatin (a chemotherapy drug) with a new drug called cetuximab in patients with locally advanced head and neck cancer

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

Final Accrual

60

Trial Chairperson

Assoc Prof June Corry, Peter MacCallum Cancer Centre, VIC
Prof Danny Rischin, Peter MacCallum Cancer Centre, VIC

Clinical Trial Registration

Related Post

26 September, 2026

Trial finds radiation therapy halves risk of brain tumour recurrence after surgery

LATEST NEWS: 26 September 2026 Giving radiotherapy after surgery

17 September, 2026

Meet the TROG Quality Assurance team

TROG UPDATES: 17 September 2026 Our Quality Assurance team